HanAll Biopharma Co Ltd (009420):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:HanAll Biopharma Co Ltd (009420) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3489
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
HanAll Biopharma Co Ltd (HanAll), formerly HanAll Pharmaceutical Co Ltd, is a pharmaceutical company that offers drug delivery, biotherapeutics, and small molecule discovery programs. The company develops drugs in therapeutic areas of ophthalmology, immunology, cardiovascular disease, dermatology and biobetter. It offers drug research and development, medical information and advanced products. HanAll operates through its research and development center and biotechnology research institute. The company’s products are used in treatment of autoimmune diseases, dry eye diseases, and recurrent and intractable cancer. It has operations in South Korea and the US. HanAll is headquartered in Seoul, South Korea.

HanAll Biopharma Co Ltd (009420) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
HanAll Biopharma Enters into Licensing Agreement for OmniAb Antibody 11
Roivant Sciences Enters into Licensing Agreement with HanAll Biopharma 12
Harbour BioMed Enters into Licensing Agreement with HanAll Biopharma 13
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 14
Equity Offering 15
Hanall Biopharma to Raise USD0.3 Million in Public Offering of Shares 15
Acquisition 16
Yuhan Completes Acquisition Of 9.1% Stake In Hanall For US$27 Million 16
HanAll Biopharma Co Ltd – Key Competitors 17
HanAll Biopharma Co Ltd – Key Employees 18
HanAll Biopharma Co Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
HanAll Biopharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
HanAll Biopharma Enters into Licensing Agreement for OmniAb Antibody 11
Roivant Sciences Enters into Licensing Agreement with HanAll Biopharma 12
Harbour BioMed Enters into Licensing Agreement with HanAll Biopharma 13
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 14
Hanall Biopharma to Raise USD0.3 Million in Public Offering of Shares 15
Yuhan Completes Acquisition Of 9.1% Stake In Hanall For US$27 Million 16
HanAll Biopharma Co Ltd, Key Competitors 17
HanAll Biopharma Co Ltd, Key Employees 18
HanAll Biopharma Co Ltd, Other Locations 19

List of Figures
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[HanAll Biopharma Co Ltd (009420):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Coty Inc.:企業の戦略・SWOT・財務情報
    Coty Inc. - Strategy, SWOT and Corporate Finance Report Summary Coty Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • HomeWorks Tri-County Electric Cooperative Inc:企業の発電所・SWOT分析2018
    HomeWorks Tri-County Electric Cooperative Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, in …
  • Globus Medical Inc (GMED):企業の財務・戦略的SWOT分析
    Globus Medical Inc (GMED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • SDX Energy Inc (SDX):石油・ガス:M&Aディール及び事業提携情報
    Summary SDX Energy Inc (SDX), formerly Sea Dragon Energy Inc., is an independent upstream company. It carries out the exploration, development and production of crude oil and natural gas liquids. The company’s primary areas of focus are Morocco and Egypt. Its principal operations are currently conce …
  • Hitachi Zosen Corp (7004):電力:M&Aディール及び事業提携情報
    Summary Hitachi Zosen Corp (Hitz) is an industrial and engineering company. It designs, constructs and operates refuse incineration and recycling facilities, pressure vessels, marine diesel engines, and press machines, and other process machine. The company also provides after-sales servicing and ma …
  • Petroleum Development Oman LLC:企業の戦略的SWOT分析
    Petroleum Development Oman LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Imricor Medical Systems Inc-医療機器分野:企業M&A・提携分析
    Summary Imricor Medical Systems Inc (Imricor) is a medical device company that offers MRI equipments. The company offers products which include cardiac ablation systems, vision MR EP ablation catheter and horizon MR EP recording system. Its vision MR EP ablation catheter is used to operate in a MRI …
  • IntelliCell BioSciences Inc:企業の戦略的SWOT分析
    IntelliCell BioSciences Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • AXA Egypt:企業の戦略・SWOT・財務情報
    AXA Egypt - Strategy, SWOT and Corporate Finance Report Summary AXA Egypt - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Sysco Corporation:企業の戦略・SWOT・財務分析
    Sysco Corporation - Strategy, SWOT and Corporate Finance Report Summary Sysco Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • TissueGen Inc:企業の製品パイプライン分析2018
    Summary TissueGen Inc (TissueGen) is a medical device company that develops fiber for advance drug delivery, nerve regeneration and tissue engineering. The company’s products comprise pharmaceutical fibers, growth factor fibers and stent. It offers pharmaceutical fibers and growth factor fibers. Tis …
  • Lockton, Inc:企業の戦略・SWOT・財務情報
    Lockton, Inc - Strategy, SWOT and Corporate Finance Report Summary Lockton, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • H. Lee Moffitt Cancer Center & Research Institute Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary H. Lee Moffitt Cancer Center & Research Institute Inc (Moffitt) is a healthcare service provider. It is engaged in the development of early stage translational research aimed at the rapid translation of scientific discoveries to benefit patient care. The center offers medical services such a …
  • Alaska Air Group, Inc.:戦略・SWOT・企業財務分析
    Alaska Air Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Alaska Air Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • CNP Assurances SA:企業の戦略・SWOT・財務情報
    CNP Assurances SA - Strategy, SWOT and Corporate Finance Report Summary CNP Assurances SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Bank CIC (Switzerland) Ltd.:企業の戦略・SWOT・財務情報
    Bank CIC (Switzerland) Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank CIC (Switzerland) Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Disproquima S.A.:戦略・SWOT・企業財務分析
    Disproquima S.A. - Strategy, SWOT and Corporate Finance Report Summary Disproquima S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Aarti Industries Ltd (AARTIIND):企業の財務・戦略的SWOT分析
    Summary Aarti Industries Ltd (Aarti Industries) is a chemical company that manufactures and markets benzene based basic and intermediate chemicals. It offers chemicals, pharma products and surfactants including rubber chemicals, dyes and pigment intermediates; surfactant intermediates, pharmaceutica …
  • AstraZeneca UK Ltd-製薬・医療分野:企業M&A・提携分析
    Summary AstraZeneca UK Ltd (AstraZeneca), a subsidiary of AstraZeneca Plc is a provider of asthma treatment solutions. The company offers research and develops various novel and targeted medicines. It offers its medicines in therapeutic areas which include cardiovascular; oncology, respiratory, infl …
  • T-Mobile US Inc (TMUS):企業の財務・戦略的SWOT分析
    T-Mobile US Inc (TMUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆